Dialysis provider DaVita Inc. (NYSE: DVA) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.1% year on year to $3.38 billion. Its non-GAAP profit of $2.95 per share was 7.3% above analysts’ consensus estimates.

Is now the time to buy DVA? Find out in our full research report (it’s free).

StockStory’s Take

DaVita’s second quarter was met with a significant negative market reaction, as shares declined sharply despite management delivering results that surpassed Wall Street’s expectations for revenue and adjusted profit. The quarter was marked by two main operational challenges: a decline in treatment volumes and lingering effects from a major cyberattack earlier in the year. CEO Javier Rodriguez noted that while the business managed to deliver on financial commitments, “the strong performance in patient care costs more than offset cyber-related weakness in revenue per treatment and volume.” Management acknowledged that missed treatments and lower admissions—primarily linked to the cyber incident and a severe flu season—were the central factors affecting growth during the period.

Looking forward, DaVita’s guidance is shaped by a mix of ongoing cost discipline and investment in clinical innovation, as well as persistent uncertainty regarding patient volumes. CFO Joel Ackerman reiterated that the company expects continued cost efficiencies, primarily from improved labor productivity and better staff retention. At the same time, management is prioritizing the adoption of new technologies and protocols, with Rodriguez stating, “We’re entering a new wave of clinical innovation that holds exciting potential for the patients we serve.” The outlook remains cautious due to elevated mortality rates and missed treatments, but leadership is confident in its ability to manage through these headwinds while pursuing long-term growth drivers.

Key Insights from Management’s Remarks

Management pointed to several factors influencing the quarter, including patient volume weakness from the cyberattack and a focus on operational efficiency to maintain profitability.

• Cyber incident impacts volume: The cyberattack earlier in the year led to a spike in missed treatments and delayed patient admissions, which management identified as key reasons for the 1.1% decline in U.S. treatment volumes. These disruptions also lowered revenue per treatment due to manual claim processing and challenges in securing prior authorizations.
• Cost control offsets revenue headwinds: Despite weaker volumes, DaVita achieved better-than-expected profitability through tight cost management, particularly in labor productivity. Improved staff retention and more efficient training contributed to lower patient care costs per treatment, helping the company absorb revenue pressures.
• Binder volume and adherence issues: Lower-than-expected dispensing of phosphate binders—medications that help manage blood phosphate levels in dialysis patients—further weighed on both revenue and costs. Management attributed this to patient adherence challenges and a shift toward over-the-counter alternatives, rather than changes in patient mix.
• Mortality and missed treatment trends: Elevated mortality rates, which management believes are a post-COVID national trend across healthcare, and persistent missed treatments continued to challenge growth. Rodriguez noted that mortality remains “higher than pre-COVID, but consistent with last year,” and acknowledged the need for a multipronged strategy to address these issues.
• Early revenue recognition in value-based care: The company’s Integrated Kidney Care (IKC) business recognized revenue earlier than anticipated due to accounting changes, though management emphasized this was a timing benefit and not indicative of improved underlying trends.

Drivers of Future Performance

For the rest of the year, DaVita’s outlook hinges on maintaining cost efficiencies while responding to ongoing volume pressures and investing in new clinical technologies.

• Labor productivity and cost management: Management expects continued gains in operational efficiency from higher staff retention and technology-enabled productivity, which should help offset headwinds from lower treatment volumes and muted revenue growth per treatment.
• Mortality and volume recovery: The company faces ongoing uncertainty regarding patient volumes due to elevated mortality and missed treatments. Rodriguez described a “three-pronged plan” to address this, including adopting advanced dialysis technologies, encouraging uptake of new drug classes like GLP-1s, and deploying predictive protocols to reduce hospitalizations.
• Innovation and regulatory environment: DaVita is closely monitoring the adoption of high-volume hemodiafiltration and next-generation dialyzers, which could improve patient outcomes and gradually support volume growth. However, management cautioned that these innovations will take years to meaningfully impact financial results. Regulatory updates, such as the Centers for Medicare & Medicaid Services (CMS) ESRD rule, remain a source of reimbursement uncertainty.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the trajectory of missed treatment and mortality rates, (2) the impact of further labor productivity initiatives and cost control measures on margins, and (3) progress in the adoption of new dialysis technologies and protocols. Developments in reimbursement policy and further integration within the value-based care business will also be important markers for DaVita’s execution.

DaVita currently trades at $132.08, down from $140.96 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.